At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABIO ARCA biopharma
Closed Christmas Day 08-30 16:00:00 EDT
28.80
+0.00
0.00%
High28.80
Low28.80
Vol0.00
Open28.80
D1 Closing28.80
Amplitude0.00%
Mkt Cap849.32M
Tradable Cap137.90M
Total Shares29.49M
T/O688.27K
T/O Rate0.00%
Tradable Shares4.79M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Oruka Therapeutics Announces Closing of Merger with ARCA biopharma
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.